NCT00623636

Phase 3 Study of MAP0004 in Adult Migraineurs

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extension.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 902 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	MAP0004	MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
DRUG	Placebo	Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.

Timeline

• Start date: 2008-07-01
• Primary completion: 2010-12-01
• Completion: 2011-01-01
• First posted: 2008-02-26
• Last updated: 2014-01-09
• Results posted: 2013-10-29

Locations

1 site across 1 country: United States